fda warning letters glp-1 compounding september 26 2025 issues 30 to online compounders 🚨 FDA Moves to Permanently

Why the timing of this research matters: The GLP-1 compounding market is in active regulatory transition as of June 2026

2017, doi: 10.3390/brainsci7020020 [DOI] [PMC free article] [PubMed] [Google Scholar] Rosenfeld Manuela, and Ladiges Warren

7 Still, Le, who is also a general surgery registrar at Royal Melbourne Hospital, says, I think it is too early to say this is a robust, durable, and generalizable effect given the high heterogeneity of underlying studies. He notes a need for more rigorous randomized controlled trials with longer follow-up times to better characterize the impact of these medications on weight and OSA together, as well as gain a better understanding of effect size, optimal doses, side effects, interactions with other medications, and impacts on other comorbidities

A plateau and maintenance can look similar on the scale, but they are not the same